Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

@article{Fernndez2015DualTO,
  title={Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.},
  author={Elena V Fern{\'a}ndez and Kelie M. Reece and Ariel M. Ley and Sarah M Troutman and Tristan Sissung and Douglas K. Price and Cindy H. Chau and William D. Figg},
  journal={Molecular pharmacology},
  year={2015},
  volume={87 6},
  pages={1006-12}
}
Enzalutamide is a potent second-generation androgen receptor (AR) antagonist with activity in metastatic castrate-resistant prostate cancer (CRPC). Although enzalutamide is initially effective, disease progression inevitably ensues with the emergence of resistance. Intratumoral hypoxia is also associated with CRPC progression and treatment resistance. Given that both AR and hypoxia inducible factor-1 α (HIF-1α) are key regulators of these processes, dual targeting of both signaling axes… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Hypoxia enhances ligand-occupied androgen receptor activity.

Biochemical and biophysical research communications • 2012
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…